Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TAK vs ZTS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TAK Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 6–4 Matrix Metrics)

TAK Overall Winner 6-Pillar Tally: TAK 4 – 2 ZTS Matrix Metrics: TAK 6 – 4 ZTS

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Zoetis Inc. (ZTS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas ZTS carries 47.2/100 (HOLD) at $83.42 (13.1x Forward P/E, 37.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TAK vs ZTS
TAK NYSE Head-to-Head Winner
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Pharmaceutical Preparations
$21.61
+0.86% 1D
Market Cap $67.5B
TTM Revenue $25.7B
Forward P/E 12.7x
Beta / 30D Vol -0.02β · 22% Vol
Unified Composite Score
47.7 / 100 HOLD
Tech 42.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (5.9% over 20 days), RSI 73
RSI-14: 73.1 · SMA20: $20.72 · SMA50: $19.46
ZTS NYSE
Zoetis Inc.
Pharmaceutical Preparations
$83.42
-0.48% 1D
Market Cap $33.7B
TTM Revenue $9.49B
Forward P/E 13.1x
Beta / 30D Vol 0.53β · 49% Vol
Unified Composite Score
47.2 / 100 HOLD
Tech 56.0 Fund 60.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (3.1% over 20 days), RSI 60
RSI-14: 59.6 · SMA20: $81.67 · SMA50: $76.46

6-Pillar Scorecard Institutional Category Breakdown (TAK 4 – 2 ZTS)

Columns: Metric · TAK · ZTS
1. Valuation Multiples TAK
Forward P/E 12.7x 13.1x
Trailing P/E N/M 14.1x
PEG Ratio 0.47x 15.37x
EV / Revenue 2.6x 4.4x
2. Growth & Scale TAK
Revenue Growth (YoY) +6.7% -1.3%
Earnings Growth (YoY) -9.8% -11.8%
TTM Revenue (USD) $25.7B $9.49B
Market Cap $67.5B $33.7B
3. Profitability & Quality ZTS
Gross Margin 64.8% 71.6%
Operating Margin 16.6% 37.9%
Net Profit Margin 0.9% 26.4%
Return on Equity (ROE) 0.6% 57.6%
4. Balance Sheet & Cash Flow TAK
Cash Generation (TTM) $7.48B EBITDA $2.28B
Cash Flow Margin 29.1% EBITDA Mgn 24.0%
Net Cash / Leverage $14.68 Book/Sh · 0.6% ROE $7.91B Net Debt (2.80x D/E)
Dividend Yield 2.92% 2.53%
5. Options & Positioning ZTS
Options Structure Phase UNCLASSIFIED SURGE
Current IV / %ile 22.4% (5th %ile) 43.4% (17th %ile)
Put/Call OI Skew Thin ADR Chain 1.17x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup ACCUMULATION · Markup
6. R&D & Supply-Chain Moat TAK
OpEx & R&D Intensity 48.2% of Rev ($12.4B) 33.7% of Rev ($3.20B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat High-Margin Pricing Power Moat
Supply-Chain Role Drug Manufacturers - Specialty & Generic Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TAK (6) vs ZTS (4)
Institutional Metric TAK ZTS Criterion Row Edge
Market Capitalization
Scale
$67.5B $33.7B Larger Scale TAK
Trailing P/E Ratio
Valuation
N/M 14.1x Lower Multiple ZTS
Forward P/E Ratio
Valuation
12.7x 13.1x Lower Multiple TAK
Revenue Growth (YoY)
Growth
+6.7% -1.3% Higher Growth TAK
Operating Margin (TTM)
Profitability
16.6% 37.9% Higher Margin ZTS
Net Profit Margin
Profitability
0.9% 26.4% Higher Margin ZTS
Return on Equity (ROE)
Capital Efficiency
0.6% 57.6% Higher ROE ZTS
52-Week Range Position
Momentum
97% ($14–$22) 23% ($69–$132) Stronger Trend TAK
Beta / 30D Volatility
Risk Regime
-0.02β · 22% Vol 0.53β · 49% Vol Lower Realized Risk TAK
Unified Institutional Score
Composite Signal
47.7 / 100 (HOLD) 47.2 / 100 (HOLD) Higher Composite TAK
Trailing 12M Revenue (USD)
Operating Scale
$25.7B $9.49B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
64.8% 71.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.47x PEG · 2.6x EV/Rev 15.37x PEG · 4.4x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$7.48B EBITDA ($14.68 Book/Sh · 0.6% ROE) $2.28B ($7.91B Net Debt (2.80x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon TAK +4.8 pp
TAK: +9.89% · ZTS: +5.09%
3M Horizon TAK +6.96 pp
TAK: +19.75% · ZTS: +12.79%
6M Horizon TAK +23.12 pp
TAK: +30.45% · ZTS: +7.33%
1Y Horizon TAK +82.94 pp
TAK: +51.79% · ZTS: -31.15%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TAK vs ZTS. Trailing 12-month operating profitability (TAK 16.6% vs ZTS 37.9%) and valuation multiples (TAK 12.7x vs ZTS 13.1x Forward P/E) are benchmarked directly in Pillar 4 below.

TAK ADR TTM Benchmark FX-Normalized USD
TTM Revenue$25.7B
Gross Margin64.8%
Op. Margin16.6%
ROE / Fwd P/E0.6% · 12.7x
ZTS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$9.49B
Gross Margin71.6%
Op. Margin37.9%
ROE / Fwd P/E57.6% · 13.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TAK UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 22.4%
IV Percentile 5th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ZTS SURGE
8d in phase · OBV ACCUMULATION
Current IV 43.4%
IV Percentile 17th %ile
Put/Call OI Skew 1.17x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact ZTS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TAK Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $67.5B market capitalization and 16.6% operating margin.
OpEx & R&D Reinvestment 48.2% of Rev ($12.4B)
90D Engineering Disclosures 0 Published
ZTS Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $33.7B market capitalization and 37.9% operating margin.
OpEx & R&D Reinvestment 33.7% of Rev ($3.20B)
90D Engineering Disclosures 0 Published

Investor FAQ TAK vs ZTS Key Questions & Quantitative Answers

As of Nov 16, 2026, Takeda Pharmaceutical Company Limited (TAK) is the stronger overall head-to-head candidate over Zoetis Inc. (ZTS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). TAK carries a Unified Composite Score of 47.7/100 (HOLD) at $21.61 (12.7x Forward P/E, 16.6% operating margin), whereas ZTS carries 47.2/100 (HOLD) at $83.42 (13.1x Forward P/E, 37.9% operating margin). Technically, TAK sits in a Markup phase (RSI 73.1, UNCLASSIFIED options structure) and ZTS sits in a Markup phase (RSI 59.6, SURGE options structure).

TAK leads the Growth & Scale pillar: TAK posts +6.7% YoY revenue growth and -9.8% YoY earnings growth on $25.7B TTM revenue (64.8% gross margin, 16.6% operating margin), compared with ZTS at -1.3% YoY revenue growth and -11.8% YoY earnings growth on $9.49B TTM revenue (71.6% gross margin, 37.9% operating margin). On trailing 12-month operating scale, TAK generates $25.7B in USD-normalized revenue versus $9.49B for ZTS. In operating R&D and SG&A reinvestment, TAK deploys 48.2% of Rev ($12.4B) (0 90-day corporate R&D disclosures) versus 33.7% of Rev ($3.20B) (0 disclosures) for ZTS.

TAK screens cheaper on headline valuation multiples. TAK trades at 12.7x Forward P/E, N/M Trailing P/E, 0.47x PEG, and 2.6x EV/Revenue (29.1% EBITDA margin), whereas ZTS trades at 13.1x Forward P/E, 14.1x Trailing P/E, 15.37x PEG, and 4.4x EV/Revenue (24.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TAK (0.6% ROE) versus ZTS (57.6% ROE) capital efficiency.

In options market volatility and institutional positioning, TAK carries 22.4% implied volatility (5th %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.02β · 22% Vol realized risk). By comparison, ZTS carries 43.4% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.17x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a SURGE options structure phase (0.53β · 49% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) Research Suite

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.